Angus Smith has notified Affimed N.V. (the “Company” or “Affimed”) of his intention to resign as the Chief Financial Officer of the Company
effective as of December 31, 2023. Mr. Smith plans to become the chief financial officer of a Boston-based biotech company. Dr. Arndt Schottelius has
also notified the Company of his intention to resign as the Chief Scientific Officer of the Company effective as of the end of May 2024 and, during this
period, he will support the search for his replacement. Dr. Schottelius plans to become the chief executive officer of a European biotech company.
The Company has commenced a process with an executive search firm for a new permanent CFO. As part of the transition plan, the Company
announced that the experienced financial and biotechnology industry executive Harry Welten will resign as a member of the Supervisory Board and
assume the operating responsibilities of interim CFO as of December 31, 2023 and will continue to operate in that capacity until a permanent successor
has been appointed. Mr. Welten has more than 20 years of U.S. and European executive management experience in the biotechnology, pharmaceutical
and banking industries, and has served as CFO for several publicly traded biotechnology companies, including Kuros Biosciences AG (formerly Cytos
Biotechnology AG), Horizon Pharma AG (formerly Nitec Pharma AG) and Arpida AG.
“Both Angus and Arndt have had a major impact on the Company over the past three and a half years. Angus led the company to successfully
raise over $250 million in equity in challenging market conditions for biotech,” said Adi Hoess, Chief Executive Officer of the Company. “These funds
have enabled Affimed to continue clinical development of its three clinical programs. Arndt has led our innovative discovery teams resulting in
continuous improvement of our ROCK® platform and building ICE® molecules for Affimed and partners such as Genentech and Roivant. We
acknowledge and recognize Arndt and Angus’ contributions and wish them both success in their future endeavors.”
“It has been an honor to serve as CFO of Affimed for the last three and a half years,” said Mr. Smith. “I want to thank the Management and
Supervisory Boards for welcoming me to the Company and for their support over the years. I am confident in the financial strength of the Company and
believe it is well positioned for success.”
“I would like to thank all members of the Management and Supervisory Boards for their continuous support over the past three and a half years,”
said Dr. Arndt Schottelius. “It has been a distinct privilege to serve as the CSO of Affimed during this period of growth in the Company’s clinical
programs and ongoing scientific discovery. With a strong platform and upcoming multiple data inflection points in three clinical programs, I feel certain
that the company is slated for success and will continue to fulfill its mission to fight cancer and improve the lives of patients through its groundbreaking